This HTML5 document contains 132 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n12http://dx.doi.org/10.1136/
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q45766371
rdf:type
wikibase:Item
schema:description
article scientifique სამეცნიერო სტატია bilimsel makale наукова стаття, опублікована в серпні 2013 2013年の論文 articolo scientifico 2013年学术文章 scientific article published on 12 August 2013 artículu científicu artigo científico tudományos cikk 2013年学术文章 artikulong pang-agham 2013年学术文章 ১২ আগস্ট ২০১৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ บทความทางวิทยาศาสตร์ 2013年學術文章 artículo científico publicado en 2013 научни чланак wetenschappelijk artikel vedecký článok 2013年學術文章 مقالة علمية نشرت في 12 أغسطس 2013 scienca artikolo videnskabelig artikel scientific article published on 12 August 2013 article científic мақолаи илмӣ artigo científico 2013年学术文章 научна статия naučni članak article scientific wissenschaftlicher Artikel 2013年學術文章 2013年学术文章 научни чланак vitskapeleg artikkel articol științific vetenskaplig artikel vědecký článek 2013 թվականի օգոստոսի 12-ին հրատարակված գիտական հոդված artikel ilmiah artykuł naukowy מאמר מדעי artigo científico scientific article published on 12 August 2013 artikull shkencor 2013년 논문 2013年学术文章 научная статья bài báo khoa học 2013年學術文章 teaduslik artikkel επιστημονικό άρθρο tieteellinen artikkeli vitenskapelig artikkel 2013 nî lūn-bûn 2013年學術文章
p:P577
wds:Q45766371-60D08BCA-45FB-4CB9-8584-77C179F131AE
wdt:P577
2013-08-12T00:00:00Z
p:P407
wds:Q45766371-4B13893E-2816-4C55-96D4-87E77860F351
wdt:P407
wd:Q1860
p:P2860
wds:Q45766371-0E61210C-5083-427E-AF4B-D33AD3721476 wds:Q45766371-1A86CF66-16AC-4498-8DBF-32C05BB6E210 wds:Q45766371-1E395FD1-4AA0-4AAA-9962-10DAC1506453 wds:Q45766371-34A68477-5C47-4344-ABF3-EB11A50ED280 wds:Q45766371-3B7624BF-D859-474E-B66C-1FA85E2CFCCA wds:Q45766371-3E27E64A-5E89-4111-97D5-1E011AEC1A72 wds:Q45766371-599D11ED-B0AF-466D-B6B1-B496FDD46CF9 wds:Q45766371-5DCE4084-8FE1-4BD3-8F56-02E852DF9CC1 wds:Q45766371-7B31CC6B-5B89-46DF-938F-21148D2B3A42 wds:Q45766371-87E2D07D-2F17-4B15-B559-DC5080725309 wds:Q45766371-9CA0340C-B25D-43D6-8BE0-79CF52DD1CAF wds:Q45766371-A65B46EB-0511-4AB0-81A3-2B7FA6370F14 wds:Q45766371-B97B0449-F89E-425C-AF96-2F5C543A6E2A wds:Q45766371-CAAF76ED-BD9B-475D-9106-4B5E3839D80D
wdt:P2860
wd:Q34315745 wd:Q51768791 wd:Q44191676 wd:Q35139581 wd:Q56879288 wd:Q38065452 wd:Q34462557 wd:Q36204125 wd:Q29619183 wd:Q37682875 wd:Q34110066 wd:Q45845892 wd:Q37374953 wd:Q46976231
p:P2093
wds:Q45766371-13057AC8-361A-4153-97C1-18951DF8F94A wds:Q45766371-0956BD35-CB37-4656-B003-22EB955F0BE4
wdt:P2093
Equity in Clinical Eligibility Criteria for RA treatment Working Group Tuulikki Sokka
rdfs:label
Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
skos:prefLabel
Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
schema:name
Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
p:P50
wds:Q45766371-D8BCF193-5166-4AAA-BBD1-1C2ED0BC78F8 wds:Q45766371-A9E45C73-8026-4433-8889-76B0BCE7709B wds:Q45766371-7D423D78-957B-4F23-95DC-9CFD5805CEC7 wds:Q45766371-9111004B-DB00-4E8E-8F74-79E931382AC4 wds:Q45766371-316562BD-2212-4193-A9F8-3914119DFB12
wdt:P50
wd:Q85633071 wd:Q39272238 wd:Q91062233 wd:Q65660760 wd:Q39184066
p:P1476
wds:Q45766371-C8B5938D-DF95-4B1E-9EA4-E74F215AE85F
wdt:P1476
Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
p:P304
wds:Q45766371-95EBC26A-883C-4D4E-9902-1EF4CD589F29
wdt:P304
2010-2021
p:P31
wds:Q45766371-546B18E4-CABE-4AD2-8F2C-B1302D8061E3
wdt:P31
wd:Q13442814
p:P698
wds:Q45766371-3CFA5455-95EF-4796-B508-EDADC62C72A1
wdtn:P698
n11:23940213
wdt:P698
23940213
p:P1433
wds:Q45766371-DA82DD8A-5116-4471-B6F0-A3DFD578B488
wdt:P1433
wd:Q4767876
p:P433
wds:Q45766371-9A3F9398-9BB1-4C8C-9F62-84BF4CCA11CE
p:P478
wds:Q45766371-D0ACDD53-D97E-4FA7-A582-8BDAD6A24AA2
wdt:P433
11
wdt:P478
73
p:P356
wds:Q45766371-0A4599AF-F581-4838-A46A-D8DF5890EC84
wdtn:P356
n12:ANNRHEUMDIS-2013-203819
wdt:P356
10.1136/ANNRHEUMDIS-2013-203819
p:P5875
wds:Q45766371-5F30E4DE-7E54-479E-BC31-85D1CCE6F496
wdt:P5875
277679837